Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06159335 · ClinicalTrials.gov registry record · Phase 3

18F-FLUC PET/MR in Patients With Brain Mets

A Phase 3 study of Radiation Therapy and Brain Metastasis, sponsored by University of Wisconsin, Madison.

Recruiting
Registry status
Phase 3
Development phase
30
Enrollment target
1
Study location

NCT06159335: Recruiting Phase 3 study of Radiation Therapy and Brain Metastasis, sponsored by University of Wisconsin, Madison.

NCT06159335 is a Phase 3 study of Radiation Therapy and Brain Metastasis that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 30 participants, below the 165-participant average among 7 other Radiation Therapy trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06159335, a Phase 3 study of Radiation Therapy and Brain Metastasis, is actively recruiting participants, sponsored by University of Wisconsin, Madison.

RECRUITING
Registry status
Phase 3
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining. Participants will undergo a single PET/MRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.

Primary Outcome

Using 18F-Fluciclovine PET, compare amino acid uptake into brain tumor tissue with uptake in normal brain tissue. Higher uptake is hypothesized to indicate malignancy

Conditions Studied

Radiation Therapy Brain Metastasis Immunotherapy, Active

Interventions

  • RADIATION F-Fluciclovine radiotracer

Study Locations (1)

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-10
Est. Completion 2026-06
Phase Phase 3
University of Wisconsin, Madison

1,039 total trials

What NCT06159335 shows while recruiting

NCT06159335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 165-participant average among 7 other Radiation Therapy trials with a reported enrollment target (82% lower).

The record links to 3 conditions, with Radiation Therapy appearing as the primary indexed condition, and to 1 intervention - of which F-Fluciclovine radiotracer is the first listed.

NCT06159335 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06159335 about?

NCT06159335 is a clinical study titled "18F-FLUC PET/MR in Patients With Brain Mets". The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerou...

What is the current status of trial NCT06159335?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2024-01-10. Estimated completion is 2026-06.

What conditions does trial NCT06159335 study?

This clinical trial studies the following conditions: Radiation Therapy, Brain Metastasis, Immunotherapy, Active.

What interventions are being tested in trial NCT06159335?

The interventions under investigation include: F-Fluciclovine radiotracer (RADIATION).

Who is sponsoring clinical trial NCT06159335?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06159335 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Radiation Therapy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06159335

Source: ClinicalTrials.gov NCT06159335, the US trial registry maintained by the National Library of Medicine. NCT06159335 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.